Developing a vaccine against the Ebola virus: Latest updates on trials and funding
International health organizations have announced an intensification of their extraordinary efforts to act swiftly and contain the spread of deadly epidemics in Africa. Medical bodies are racing against time to develop a vaccine against the Ebola virus, specifically targeting the Bundibugyo strain currently ravaging the Democratic Republic of Congo and Uganda. This rapid action comes after nearly 250 deaths and more than 1,100 suspected cases were recorded, presenting the international community with a new health challenge that demands an urgent and innovative response to avert a wider humanitarian catastrophe.
History of confronting the pandemic and the context of the current outbreak
Historically, the Ebola virus is one of the deadliest hemorrhagic viruses humanity has faced since it was first discovered in 1976 near the Ebola River in the Congo. Over the decades, different strains of the virus, such as the Zaire and Sudan strains, have caused outbreaks that have claimed thousands of lives, most notably the major outbreak in West Africa between 2014 and 2016. With the re-emergence of the Bundibugyo strain, the urgent need to develop targeted preventative solutions is paramount, as this strain still lacks any officially approved treatment or vaccine, making the current trials a crucial turning point in modern medical history.
Candidate vaccines and chances of success in producing a vaccine against the Ebola virus
The World Health Organization indicates that the vaccine closest to success is the single-dose rVSV vaccine, developed by the International AIDS Vaccine Initiative (IAVI). This vaccine is based on the same scientific and technological foundation used to produce the successfully licensed Ervebo vaccine against the most common Zaire strain. In this context, the non-profit organization IAVI has entered into a collaboration agreement with the University of Texas Medical Branch to accelerate the development of this vaccine.
Renowned virologist Thomas Geisbert, who previously oversaw the development of the Ervebo vaccine, explained that laboratory tests conducted on monkeys in 2013 demonstrated effective and robust protection against the Bundybuggio strain. However, the project stalled for over a decade due to a lack of funding and weak interest from major pharmaceutical companies, before resurfacing with the recent outbreak. According to the World Health Organization, it could take seven to nine months before the vaccine is ready for human clinical trials.
International funding and expected impacts on global health security
The efforts were not limited to one vaccine; the Coalition for Epidemic Preparedness Innovations (CEPI) announced generous funding to accelerate the development of three candidate vaccines against the Bundybugyo strain, which the Director-General of the World Health Organization, Tedros Adhanom Ghebreyesus, described as a very important advance.
This funding also supports a second vaccine being developed by the prestigious University of Oxford (which previously developed the AstraZeneca COVID-19 vaccine). This vaccine is expected to be produced by the Serum Institute of India, the world's largest vaccine manufacturer, and made available for clinical trials within two to three months. The third vaccine is being developed by the American pharmaceutical giant Moderna using advanced messenger RNA (mRNA) technology.
The success in producing these vaccines will not only contribute to protecting local communities in Congo and Uganda, but will extend its impact regionally and internationally to enhance global health security and prevent the transformation of a local outbreak into a global pandemic that threatens international travel and the economy, thus confirming the importance of international solidarity in the face of cross-border biological threats.
